Oruka Therapeutics, Inc.

NASDAQ:ORKA

Biotechnology

Healthcare
$95.74 +0.65%

+$0.46 today

Market cap
$6.49B
Beta
-0.30
P/E (TTM)
-33.9
EPS (TTM)
-$2.11
52W Low $10.77High $91.00

Volume 0.52M

Average 1.55M

ORKA EPS (Basic)

Net income attributable to common shareholders divided by the weighted average basic shares outstanding.

Oruka Therapeutics, Inc.NASDAQ: ORKA

EPS (Basic) · Q3 FY2026 · quarter ended Sep 2026

EPS (Basic) remains negative

Q3 FY2026 EPS (Basic) was -$0.63, compared with -$0.69 a year earlier. Trailing-twelve-month EPS (Basic) was -$2.41.

Context

  • EPS (Basic) grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether EPS (Basic) reaches the consensus estimate from 7 analysts of -$2.11 (+8.5%) for the fiscal year ending Dec 2026, a slowdown from the +53.7% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterSep 2026
-$0.63+4.5% QoQ
Last fiscal yearDec 2025
-$2.31+53.7% YoY
LTMSep 2026
-$2.41+27.2% YoY
EPS (Basic) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+8.7%-1.7%-10.4 pp
1 year+53.7%+8.5%-45.2 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EPS (Basic) history

USD · from the income statement

Latest · FY2025
(2.31) USD
Year-over-year change
+53.7%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EPS (Basic) vs competitors

How ORKA compares with its peers on the latest reported figures

  • ORKA's LTM Sep 2026 EPS (Basic) of -$2.41 is the 8th highest of the 10 companies compared; the peer median is -$1.09.
  • Its year-over-year change of +27.2% is the 4th highest of 10, against a peer median of +13.5%.
ORKA Competitors Peer median
EPS (Basic) for ORKA and competitors
Company Period LTM YoY 3-year CAGR
DNTHDianthus Therapeutics, Inc.LTM Jun 2026-$0.13 +96.0%—
ACRSAclaris Therapeutics, Inc.LTM Mar 2026-$0.56 +59.7%—
ANABAnaptysBio, Inc.LTM Mar 2026-$0.85 +82.7%—
CNTBConnect Biopharma Holdings LimitedFY2025-$1 -257.1%—
ZURAZura Bio LimitedLTM Mar 2026-$1.09 -43.4%—
ATTOAttovia Therapeutics, Inc.FY2025-$1.42 -35.2%—
XNCRXencor, Inc.LTM Jun 2026-$2.17 +13.5%—
ORKAOruka Therapeutics, Inc.LTM Sep 2026-$2.41 +27.2%—
ALMSAlumis Inc. Common StockLTM Jun 2026-$3.8 +15.7%—
MLTXMoonLake ImmunotherapeuticsLTM Mar 2026-$3.88 -68.7%—
ODTXOdyssey Therapeutics, Inc.—— ——
Peer median (excluding ORKA) -$1.09+13.5%—

Competitors are the stored peer set for ORKA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue91K114K111K27K83K
Gross Profit(91K)(114K)(111K)(27K)(83K)
Gross Margin—————
Research & Development13.83M4.46M1.01M75.06M100.64M
Selling, General & Admin5.41M5.26M6.17M13.04M21.33M
Operating Expenses19.24M9.73M7.19M88.1M121.97M
Depreciation & Amortization91K114K111K27K83K
EBITDA(19.23M)(9.81M)(5.23M)(82.23M)(105.35M)
EBITDA Margin—————
Operating Income(19.34M)(9.84M)(7.3M)(88.12M)(122.05M)
Operating Margin—————
Interest Income0675K1.96M5.86M16.63M
Interest Expense0001.47M0
Other Income / Expenses13K(85K)1.96M4.4M16.62M
Income Before Tax(19.32M)(9.93M)(5.34M)(83.72M)(105.43M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(19.32M)(9.93M)(5.34M)(83.72M)(105.43M)
Net Margin—————
EPS (Basic)(16.68)(8.27)(4.44)(4.99)(2.31)
EPS (Diluted)(16.68)(8.27)(4.44)(4.99)(2.31)
Weighted Avg Shares13.9M14.41M14.42M16.79M45.61M
Weighted Avg Shares (Diluted)13.9M14.41M14.42M16.79M45.61M

Oruka Therapeutics, Inc.

NASDAQ:ORKA

Intrinsic Alpha fair value

Locked

Current Price

$95.74

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.